Your browser doesn't support javascript.
loading
Cost-effectiveness of Xpert®MTB/RIF in the diagnosis of tuberculosis: pragmatic study
Silva, Suely Conceição Alves da; Vater, Maria Claudia; Ramalho, Daniela Maria de Paula; Almeida, Isabela Neves de; Miranda, Silvana Spíndola de; Kritski, Afrânio.
  • Silva, Suely Conceição Alves da; Universidade Federal do Rio de Janeiro. Programa Acadêmico de Tuberculose. Rio de Janeiro. BR
  • Vater, Maria Claudia; Universidade Federal do Rio de Janeiro. Programa Acadêmico de Tuberculose. Rio de Janeiro. BR
  • Ramalho, Daniela Maria de Paula; Universidade Federal do Rio de Janeiro. Programa Acadêmico de Tuberculose. Rio de Janeiro. BR
  • Almeida, Isabela Neves de; Universidade Federal de Minas Gerais. Faculdade de Medicina. Laboratório de Pesquisa em Micobactérias. Belo Horizonte. BR
  • Miranda, Silvana Spíndola de; Universidade Federal de Minas Gerais. Faculdade de Medicina. Laboratório de Pesquisa em Micobactérias. Belo Horizonte. BR
  • Kritski, Afrânio; Universidade Federal do Rio de Janeiro. Programa Acadêmico de Tuberculose. Rio de Janeiro. BR
Rev. Soc. Bras. Med. Trop ; 54: e07552020, 2021. tab
Article in English | LILACS | ID: biblio-1155600
ABSTRACT
Abstract

INTRODUCTION:

The intensification of research and innovation with the creation of networks of rapid and effective molecular tests as strategies for the end of tuberculosis are essential to avoid late diagnosis and for the eradication of the disease. We aimed to evaluate the cost-effectiveness of Xpert®MTB/RIF (Xpert) in the diagnosis of drug-resistant tuberculosis in reference units, in scenarios with and without subsidies, and the respective cost adjustment for today.

METHODS:

The analyses were performed considering as criterion of effectiveness, negative culture or clinical improvement in the sixth month of follow-up. The comparison was performed using two diagnostic strategies for the drug susceptibility test (DST), BactecTMMGITTM960 System, versus Xpert. The cost effectiveness and incremental cost-effectiveness ratio (ICER) were calculated and dollar-corrected for American inflation (US$ 1.00 = R$ 5,29).

RESULTS:

Subsidized Xpert had the lowest cost of US$ 33.48 (R$67,52) and the highest incremental average efficiency (13.57), thus being a dominated analysis. After the inflation was calculated, the mean cost was DST-MGIT=US$ 74.85 (R$ 396,73) and Xpert = US$ 37.33 (R$197,86) with subsidies.

CONCLUSIONS:

The Xpert in the diagnosis of TB-DR in these reference units was cost-effective with subsidies. In the absence of a subsidy, Xpert in TB-DR is not characterized as cost effective. This factor reveals the vulnerability of countries dependent on international organizations' subsidy policies.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Tuberculosis / Tuberculosis, Multidrug-Resistant / Mycobacterium tuberculosis Type of study: Diagnostic study / Health economic evaluation Limits: Humans Language: English Journal: Rev. Soc. Bras. Med. Trop Journal subject: Tropical Medicine Year: 2021 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Federal de Minas Gerais/BR / Universidade Federal do Rio de Janeiro/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Tuberculosis / Tuberculosis, Multidrug-Resistant / Mycobacterium tuberculosis Type of study: Diagnostic study / Health economic evaluation Limits: Humans Language: English Journal: Rev. Soc. Bras. Med. Trop Journal subject: Tropical Medicine Year: 2021 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Federal de Minas Gerais/BR / Universidade Federal do Rio de Janeiro/BR